The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
NG LaRocca, LD Hudson, R Rudick… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was
formed by the National MS Society to develop improved measures of multiple sclerosis (MS) …
formed by the National MS Society to develop improved measures of multiple sclerosis (MS) …
[HTML][HTML] Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis
CI Coleman, MF Sidovar, MS Roberts, C Kohn - PloS one, 2013 - journals.plos.org
This study was conducted to estimate the indirect costs and health-related quality of life
(HRQoL)(utilities) of multiple sclerosis (MS) patients in the United States (US), and to …
(HRQoL)(utilities) of multiple sclerosis (MS) patients in the United States (US), and to …
Walking speed and health‐related quality of life in multiple sclerosis
Objective The aim of this study was to evaluate the association between slower walking and
health-related quality of life (HRQoL) in multiple sclerosis (MS) patients. Methods We used …
health-related quality of life (HRQoL) in multiple sclerosis (MS) patients. Methods We used …
Mobility, walking and physical activity in persons with multiple sclerosis
Objective: The effect of differing levels of mobility and walking disability on level of physical
activity (PA) performed in persons with multiple sclerosis (PwMS) is unknown. We aimed to …
activity (PA) performed in persons with multiple sclerosis (PwMS) is unknown. We aimed to …
[HTML][HTML] Estimating a minimal clinically important difference for the EuroQol 5-Dimension health status index in persons with multiple sclerosis
CG Kohn, MF Sidovar, K Kaur, Y Zhu… - Health and Quality of Life …, 2014 - Springer
Background Limited data define what constitutes a minimal clinically important difference
(MCID) on the EuroQol 5-Dimension (EQ-5D) health status index in persons with multiple …
(MCID) on the EuroQol 5-Dimension (EQ-5D) health status index in persons with multiple …
[HTML][HTML] Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase
MF Sidovar, P Kozlowski, JW Lee, MA Collins… - Journal of Biological …, 2000 - ASBMB
The activity of the serine/threonine kinase c-Raf (Raf) is inhibited by increased intracellular
cAMP. This is believed to require phosphorylation with the cAMP-dependent protein kinase …
cAMP. This is believed to require phosphorylation with the cAMP-dependent protein kinase …
[HTML][HTML] Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
BL Limone, MF Sidovar, CI Coleman - Health and quality of life outcomes, 2013 - Springer
Background Trials have not assessed the effect of dalfampridine-extended release
(dalfampridine-ER) on health utility. We sought to evaluate the effect of dalfampridine-ER …
(dalfampridine-ER) on health utility. We sought to evaluate the effect of dalfampridine-ER …
Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients
MF Sidovar, BL Limone, S Lee, CI Coleman - BMJ open, 2013 - bmjopen.bmj.com
Objective To map the 12-item Multiple Sclerosis Walking Scale (MSWS-12) onto the EuroQol
5-dimension (EQ-5D) health-utility index in multiple sclerosis (MS) patients participating in …
5-dimension (EQ-5D) health-utility index in multiple sclerosis (MS) patients participating in …
Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control …
MF Sidovar, BL Limone, CI Coleman - Patient related outcome …, 2016 - Taylor & Francis
Background Mapping of patient-reported outcomes to the five-dimension EuroQol (EQ-5D)
health index is increasingly being used for understanding the relationship of outcomes to …
health index is increasingly being used for understanding the relationship of outcomes to …
Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
M Jara, MF Sidovar, HR Henney III - Therapeutics and Clinical …, 2014 - Taylor & Francis
Purpose This study aimed to characterize the prescribing of dalfampridine extended release
(D-ER) 10 mg tablet treatment in people with multiple sclerosis (MS). Methods A …
(D-ER) 10 mg tablet treatment in people with multiple sclerosis (MS). Methods A …